News >

Novel Imaging Slated to Change Trajectory of Prostate Cancer Treatment

Caroline Seymour
Published: Tuesday, Jan 07, 2020

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute

Hussein Aoun, MD

Novel next-generation imaging modalities have greater visibility than conventional imaging tools, leading to higher detection rates and earlier treatment of early recurrences and metastatic disease among men with prostate cancer, explained Hussein Aoun, MD.

“With MRI, we can identify clinically significant lesions and stage local disease to see if there is extraprostatic extension. In terms of metastatic or early recurrent disease, we have PET scans with agents such as 18F-fluciclovine (Axumin), where we can identify lesions earlier that we would not have seen previously with a CT scan or conventional bone scan,” said Aoun.

In an interview during the 2019 OncLive ® State of the Science Summit™ on Genitourinary Cancers, Aoun, a radiologist at Barbara Ann Karmanos Cancer Institute, discussed the use of novel imaging modalities and contrasted them with conventional imaging tools in prostate cancer.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication